EDITORIAL
Published on 31 May 2022
Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
doi 10.3389/fimmu.2022.938069
- 1,320 views
- 3 citations
- Frontiers in Immunology
- Vaccines and Molecular Therapeutics
- Research Topics
- Neutralizing Antibodies in the Prevention and Treatment of COVID-19
Neutralizing Antibodies in the Prevention and Treatment of COVID-19
23k
Total Downloads
93k
Total Views and Downloads
Submit your idea
You will be redirected to our submission process.
Articles
ORIGINAL RESEARCH
Published on 11 May 2022
Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the “Green Pass” Policy
doi 10.3389/fimmu.2022.833085
- 2,113 views
- 7 citations
REVIEW
Published on 27 Apr 2022
Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
doi 10.3389/fimmu.2022.814365
- 9,119 views
- 14 citations
ORIGINAL RESEARCH
Published on 24 Feb 2022
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
doi 10.3389/fimmu.2022.822159
- 2,322 views
- 28 citations
ORIGINAL RESEARCH
Published on 22 Feb 2022
Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
doi 10.3389/fimmu.2022.816159
- 2,073 views
- 3 citations
SYSTEMATIC REVIEW
Published on 07 Feb 2022
Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
doi 10.3389/fimmu.2022.817829
- 4,431 views
- 33 citations
ORIGINAL RESEARCH
Published on 13 Dec 2021
A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
doi 10.3389/fimmu.2021.766821
- 9,154 views
- 18 citations
ORIGINAL RESEARCH
Published on 09 Dec 2021
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
doi 10.3389/fimmu.2021.790469
- 3,614 views
- 19 citations
REVIEW
Published on 30 Nov 2021
The Global Epidemic of the SARS-CoV-2 Delta Variant, Key Spike Mutations and Immune Escape
doi 10.3389/fimmu.2021.751778
- 11,034 views
- 177 citations
ORIGINAL RESEARCH
Published on 23 Nov 2021
Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
doi 10.3389/fimmu.2021.772320
- 5,370 views
- 28 citations
ORIGINAL RESEARCH
Published on 11 Nov 2021
Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations
doi 10.3389/fimmu.2021.730099
- 4,340 views
- 17 citations
ORIGINAL RESEARCH
Published on 26 Oct 2021
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency
doi 10.3389/fimmu.2021.750386
- 5,097 views
- 12 citations
Published in
Frontiers in Immunology
- Vaccines and Molecular Therapeutics
Participating Journals
Frontiers in Public Health
Vaccines and Molecular TherapeuticsOffline
- 3.0 impact factor
- 4.8 citescore
Impact
- 93kTopic views
- 66kArticle views
- 23kArticle downloads